about
Relationship of exercise capacity and left ventricular dimensions in patients with a normal ejection fraction. An exploratory study.Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titinMyosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling.Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: If it's not one thing it's another.Relaxation and the Role of Calcium in Isolated Contracting Myocardium From Patients With Hypertensive Heart Disease and Heart Failure With Preserved Ejection Fraction.β-Blockers in myocardial infarction and coronary artery disease with a preserved ejection fraction: recommendations, mechanisms, and concerns.Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium.Left ventricular atrophy in pulmonary arterial hypertension: a sinister dexter conundrum.High dose intracoronary N-acetylcysteine in a porcine model of ST-elevation myocardial infarction.Left ventricular end-diastolic volume predicts exercise capacity in patients with a normal ejection fractionPharmacological heart rate lowering in patients with a preserved ejection fraction-review of a failing conceptHeart Rate and Heart Failure With Preserved Ejection Fraction: Time to Slow β-Blocker Use?Safety and Feasibility of a Nocturnal Heart Rate Elevation-Exploration of a Novel Treatment ConceptAssociation of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT TrialEffects of a Higher Heart Rate on Quality of Life and Functional Capacity in Patients With Left Ventricular Diastolic DysfunctionBeta-Blocker Cessation in Stable Outpatients With Heart Failure With a Preserved Ejection Fraction
P50
Q35163081-707FD83B-FCD2-4CAF-9D00-55560833EE01Q35328760-B8FE0F38-C78B-49ED-82A4-2C776BF06D9DQ36421971-1EDD8B99-E168-4B30-A85A-E2D9151835B5Q43067579-9F95DF17-A40C-4DF0-A22F-35DC91DEACEAQ47981829-1998EF7A-1613-4322-8144-6EF5A8704260Q50063200-A736B1B8-F893-4137-827E-60ED4DC352E6Q50078700-D80D40AE-C5CA-4974-95B0-95C77F7BBBD3Q53036652-4C7B1061-6C77-4337-96BC-5B79E5B5C32CQ54448636-2D95D400-AE8A-4040-86A0-D5A6274D3ABBQ88469595-BA4A035B-1191-45A2-8AD4-8D02D2D3C9A3Q89816263-CB712229-37B0-4BE2-B5AD-8D7B6648819FQ90122939-24C7A6D1-6D92-46EE-99CF-5020D798BCB8Q90347963-F6B9DF34-AFCD-45D6-B877-B0921D113F3CQ91682216-749A1DC3-0E38-49D3-AD7F-EC89789FD82FQ92505711-2DDEAFE8-215E-4963-9EEB-620E17F469A2Q93075505-0BEEA327-8A9C-4842-B540-0D3402F1CC3F
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Markus Meyer
@en
Markus Meyer
@nl
type
label
Markus Meyer
@en
Markus Meyer
@nl
prefLabel
Markus Meyer
@en
Markus Meyer
@nl
P31
P496
0000-0002-4398-5642